BRPI0614761A2 - proteìnas de fusão de albumina - Google Patents

proteìnas de fusão de albumina

Info

Publication number
BRPI0614761A2
BRPI0614761A2 BRPI0614761-5A BRPI0614761A BRPI0614761A2 BR PI0614761 A2 BRPI0614761 A2 BR PI0614761A2 BR PI0614761 A BRPI0614761 A BR PI0614761A BR PI0614761 A2 BRPI0614761 A2 BR PI0614761A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
albumin fusion
vectors
albumin
host cells
Prior art date
Application number
BRPI0614761-5A
Other languages
English (en)
Inventor
Craig Rosen
Paul Moore
Yanggu Shi
David Lafleur
Michael Laird
William Haseltine
Douglas Woods
Jason Bock
Mani Subramanian
Adam Bell
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of BRPI0614761A2 publication Critical patent/BRPI0614761A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

PROTEìNAS DE PUSãO DE ALBUMINA. A presente invenção engloba proteínas de fusão de albumina. Moléculas de ácido nucléico que codificam as proteínas de fusão de albumina da invenção também são englobadas pela invenção, assim como os vetores contendo estes ácidos nucléicos, células hospedeiras transformadas com estes vetores de ácidos nucléicos e métodos de preparar proteínas de fusão de albumina da invenção e usar estes ácidos nucléicos, vetores e/ou células hospedeiras. Adicionalmente, a presente invenção engloba composições farmacêuticas compreendendo proteínas de fusão de albumina e métodos de tratar, prevenir ou aliviar doenças, desordens ou condições usando proteínas de fusão de albumina da invenção.
BRPI0614761-5A 2005-08-12 2006-07-31 proteìnas de fusão de albumina BRPI0614761A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US70752105P 2005-08-12 2005-08-12
US71238605P 2005-08-31 2005-08-31
US73272405P 2005-11-03 2005-11-03
US77691406P 2006-02-28 2006-02-28
US78136106P 2006-03-13 2006-03-13
US81018206P 2006-06-02 2006-06-02
US81368206P 2006-06-15 2006-06-15
PCT/US2006/029391 WO2007021494A2 (en) 2005-08-12 2006-07-31 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
BRPI0614761A2 true BRPI0614761A2 (pt) 2009-05-19

Family

ID=37758042

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614761-5A BRPI0614761A2 (pt) 2005-08-12 2006-07-31 proteìnas de fusão de albumina

Country Status (13)

Country Link
EP (1) EP1924596A4 (pt)
JP (1) JP2009504157A (pt)
KR (1) KR20080071119A (pt)
AU (1) AU2006280312A1 (pt)
BR (1) BRPI0614761A2 (pt)
CA (1) CA2618476A1 (pt)
EC (1) ECSP088262A (pt)
IL (1) IL189246A0 (pt)
MA (1) MA29836B1 (pt)
MX (1) MX2008001865A (pt)
NO (1) NO20081233L (pt)
TN (1) TNSN08064A1 (pt)
WO (1) WO2007021494A2 (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
CA2405709A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
AU2007258609B2 (en) * 2006-06-07 2013-01-24 Human Genome Sciences, Inc. Albumin fusion proteins
BRPI0716744A2 (pt) * 2006-09-14 2016-10-04 Human Genome Sciences Inc proteínas de fusão de albumina
EP2450366A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
RU2567667C2 (ru) 2008-06-13 2015-11-10 Проекто Де Биомедисина Сима, С.Л. Конъюгаты для введения биологически активных соединений
US8323634B2 (en) 2009-01-16 2012-12-04 Teva Pharmaceutical Industries Ltd. Stable formulations of highly concentrated recombinant human albumin-human granulocyte colony stimulating factor
US8716448B2 (en) 2009-02-03 2014-05-06 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
EP2396347B1 (en) 2009-02-11 2017-04-12 Albumedix A/S Albumin variants and conjugates
KR20100100254A (ko) * 2009-03-05 2010-09-15 (주)바이오큐어팜 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물
CN102741280B (zh) * 2009-10-30 2015-12-02 诺维信生物制药丹麦公司 白蛋白变体
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
US9238080B2 (en) * 2010-05-21 2016-01-19 Merrimack Pharmaceuticals, Inc. Bi-specific fusion proteins
WO2012118042A1 (ja) * 2011-02-28 2012-09-07 独立行政法人国立循環器病研究センター 悪性腫瘍転移抑制用医薬
CN104011072B (zh) 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 白蛋白变体
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
GB2515941A (en) 2011-10-21 2015-01-07 Abbvie Inc Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EA201490836A1 (ru) 2011-10-21 2014-11-28 Эббви Инк. Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
NZ626945A (en) 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
KR20190094480A (ko) 2012-02-15 2019-08-13 바이오버라티브 테라퓨틱스 인크. 재조합 인자 viii 단백질
CN111548418A (zh) 2012-02-15 2020-08-18 比奥贝拉蒂治疗公司 因子viii组合物及其制备和使用方法
AU2013234299B2 (en) 2012-03-16 2017-06-22 Albumedix Ltd. Albumin variants
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
CN103525695B (zh) * 2012-07-04 2015-05-20 长沙中生众捷生物技术有限公司 便携式肾功能检测***
PT2882450T (pt) 2012-07-11 2020-02-19 Bioverativ Therapeutics Inc Complexo de fator viii com xten e a proteína fator de von willebrand, e utilizações do mesmo
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
SI3889173T1 (sl) 2013-02-15 2023-11-30 Bioverativ Therapeutics Inc. Optimiran gen dejavnika VIII
EP2956002B1 (en) 2013-02-16 2017-09-06 Albumedix A/S Pharmacokinetic animal model
AU2014228938B2 (en) 2013-03-15 2019-05-02 Bioverativ Therapeutics Inc. Factor IX polypeptide formulations
TW202003554A (zh) 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
EP3903599A1 (en) 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
SI3091997T1 (sl) 2014-01-10 2022-10-28 Bioverativ Therapeutics Inc. Himerni proteini faktorja VIII in njihova uporaba
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
PL3207130T3 (pl) 2014-10-14 2020-02-28 Halozyme, Inc. Kompozycje deaminazy adenozyny 2 (ada2), jej warianty i sposoby ich zastosowania
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
ES2863278T3 (es) 2015-10-02 2021-10-11 Silver Creek Pharmaceuticals Inc Proteínas terapéuticas biespecíficas para la reparación de tejidos
CN105254766B (zh) * 2015-10-26 2018-10-16 中国航天员科研训练中心 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用
JP7217630B2 (ja) 2016-02-01 2023-02-03 バイオベラティブ セラピューティクス インコーポレイテッド 最適化第ｖｉｉｉ因子遺伝子
CN109689063A (zh) 2016-04-28 2019-04-26 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
WO2018082758A1 (en) 2016-11-04 2018-05-11 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
CA3044838A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
TW201831521A (zh) 2017-01-31 2018-09-01 美商生物化學醫療公司 因子ｉｘ融合蛋白以及其製備方法及使用方法
MA50141A (fr) * 2017-04-20 2020-07-29 Novo Nordisk As Procédés de purification de protéines de fusion d'albumine
KR20200035130A (ko) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 이의 용도
CA3090136A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
BR112021002017A2 (pt) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. moléculas de ácido nucleico e usos das mesmas para terapia genética não viral
TW202039855A (zh) 2018-12-06 2020-11-01 美商百歐維拉提夫治療公司 表現因子ｉｘ之慢病毒載體的用途
US20210113634A1 (en) 2019-09-30 2021-04-22 Bioverativ Therapeutics Inc. Lentiviral vector formulations
WO2022030580A1 (ja) * 2020-08-06 2022-02-10 国立大学法人宮崎大学 長時間作用型新規アドレノメデュリン誘導体、その製造方法及びその医薬用途
JP2024056667A (ja) * 2022-10-11 2024-04-23 Ｊｃｒファーマ株式会社 血清アルブミンと生理活性を有する蛋白質との融合蛋白質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
CA2513213C (en) * 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA06009072A (es) * 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs

Also Published As

Publication number Publication date
ECSP088262A (es) 2008-05-30
NO20081233L (no) 2008-05-09
MX2008001865A (es) 2008-04-15
JP2009504157A (ja) 2009-02-05
WO2007021494A2 (en) 2007-02-22
EP1924596A4 (en) 2009-07-29
AU2006280312A1 (en) 2007-02-22
EP1924596A2 (en) 2008-05-28
KR20080071119A (ko) 2008-08-01
WO2007021494A3 (en) 2007-07-26
CA2618476A1 (en) 2007-02-22
MA29836B1 (fr) 2008-10-03
TNSN08064A1 (en) 2009-07-14
IL189246A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
BRPI0614761A2 (pt) proteìnas de fusão de albumina
BRPI0507026A (pt) proteìnas de fusão de albumina
MX2009002816A (es) Proteinas de fusion de albumina.
WO2007146038A3 (en) Albumin fusion proteins
WO2003059934A3 (en) Albumin fusion proteins
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
MX2019007753A (es) Polipeptidos que contienen fc con glicosilacion alterada y funcion efectora reducida.
BR112014007469A2 (pt) arcabouços de proteína com base em repetição de fibronectina tipo iii com superfícies de ligação alternativas
BR112015012152A2 (pt) Proteína de fusão terapêutica direcionada que compreende uma enzima lisossomal, ácido nucleico, composição farmacêutica, método para produzir a dita proteína e usos da proteína para tratar uma doença de armazenamento lisossomal e mucopolissacaridose tipo iiib
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
WO2001079444A3 (en) Albumin fusion proteins
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
BRPI0911385A2 (pt) mutantes fgf21 e seus usos
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
BR112012029588A2 (pt) materiais biológicas relacionados a her3.
BRPI1010880A2 (pt) polipeptídeos de hormônio de crescimento e métodos de fazer e usar os mesmos.
MX2009004243A (es) Nuevas proteinas h5, moleculas de acido nucleico y vectores que las codifican y su uso medicinal.
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
CA2818990A1 (en) Designed repeat proteins binding to serum albumin
EA201171220A1 (ru) Мутанты fgf21 и их применение
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 6A ANUIDADE.